CART-meso

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameCART-meso
Drug Alias NameCART-meso
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionMesothelin modulatorsT lymphocyte replacements
TargetsMesothelin
Therapy Area/IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPancreatic Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma AgUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Pennsylvania
Inactive CompaniesN/A
Active IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms +[5] 
Inactive IndicationsPancreatic NeoplasmsBreast NeoplasmsCarcinoma, Ovarian Epithelial +[4] 

Other Information

ATC CodeN/A
Related LinksN/A